
News|Videos|March 31, 2026
Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?
Author(s)Jeff Hall
In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.
Advertisement
Advertisement
New research suggests that the theranostic agent 177Lu-PSMA-617 may provide a significant impact in treating oligometastatic hormone-sensitive prostate cancer (HSPC) and potentially deferring the use of androgen deprivation therapy (ADT).
Related to this article

The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.

In a recent podcast episode, Jack Andrews, MD, discussed the role of PSMA PET in facilitating more targeted, metastasis-directed therapy for prostate cancer and recent phase 4 research comparing PSMA PET agents in men with low PSA values.

Uptunity | Aneurysm reportedly identifies suspected saccular brain aneurysms larger than 3 mm on head CTA and provides quantitative comparison between exams to assess changes in known aneurysms over time.

In a recent interview, Carolynn DeBenedectis, MD, discussed the utility of AI-enabled slab reconstruction for interpretation of digital breast tomosynthesis (DBT) and new research showing a 13 percent reduction in reading time.

In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the evolution, research and pearls for ablation procedures, and emerging considerations for histotripsy in the realm of interventional oncology.

In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),
Advertisement
Advertisement

